Stockreport

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

Zura Bio Limited - Class A Ordinary shares  (ZURA) 
PDF Advancing two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) and systemic sclerosis (SSc)Topline data expected from the Phase 2 TibuSHIELD study [Read more]